In Brief: Lasermedics
This article was originally published in The Gray Sheet
Executive Summary
Lasermedics: Acquires exclusive worldwide rights to manufacture, market and distribute CB Svendsen's MicroLight 830 low-level laser used for the treatment of Carpel Tunnel Syndrome. The laser is currently in U.S. clinical trials under an FDA investigational device exemption. Marketing and distribution rights were granted for a one-time payment and quarterly royalty payments based on sales over the next seven years, after which Lasermedics will have sole-ownership of the technology. Manufacturing rights were granted for a one-time payment due in June 1998. Under a separate agreement CB Svendsen will continue to manufacture the laser for Lasermedics for the international market...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.